Castle Creek Pharmaceutical LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Castle Creek Pharmaceutical LLC
Amryt’s birch bark extract oleogel-S10 for Epidermolysis Bullosa patients might become only the third botanical drug to clear the FDA.
No drugs are approved for epidermolysis bullosa and children with so-called butterfly skin are currently treated by cleaning open wounds and bandaging them. This could soon change.
Filsuvez has the potential to become the first treatment approved for epidermolysis bullosa, a rare genetic condition where skin can tear and blister at even the slightest touch.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Fibrocell Science, Inc.
- Paragon Biosciences